AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02544685 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beneo Synergy 1
Description: Dose of Beneo Synergy 1: depends on the age of the patient (full dose variation: 0,2g/100ml milk formula - 12g/daily), gradually increased as tolerated by the patient every 2-3 days in first 8-12 days
Study NCT02544685 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same dosage regimen as active drugs
Study NCT01432691 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hemi (hemialloplastik)
Description: THA vs hemi
Study NCT02505880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local anesthetic + Hypnosis
Description: Modified state of consciousness allowing to be at the same time here and somewhere else. The individual is going to dive into his imagination to extract of an uncomfortable situation. And local anesthetic (solution of Xylocaine with adrenaline 1 % dabbed in 20 % of bicarbonate of sodium 4,2 %, maximal dose of 0,5ml / kg)
Study NCT02505880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: Sufentanil intravenous (0.1 in 0.2 µg / kg) and propofol (5 in 10 mg / kg on 3 mn) administration
Study NCT03466177 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Non-invasive, multimodal retinal imaging
Description: Ocular exam including the application of different non-invasive ocular imaging techniques
Study NCT04675866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Camrelizumab, Albumin-bound paclitaxel, S-1
Description: Camrelizumab: 200mg, iv, Q3W, d1; Albumin-bound paclitaxel: 125mg/m2, iv, d1, 8, Q3W; S-1: According to the patient's body surface area, the dosage is set to 40, 50, 60 mg/time, bid, po, taking 2 weeks, and stopping the drug for 1 week as a cycle.
Study NCT03074474 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: OviTex 1S Permanent
Description: OviTex 1S Permanent is a reinforced tissue matrix consisting of layers of extra-cellular matrix derived from sheep stomachs. The layers are embroidered together with a monofilament polypropylene. One side of the mesh has blue polypropylene stitching, which provides a surface conducive to native tissue growth. The other side of the mesh is a smooth surface intended to minimize tissue attachment (adhesions).
Study NCT02179333 — intervention group
Intervention type: OTHER
Intervention: Ataxia rating scale
Description: Administer new rating scale for ataxia. This will be administered by two different raters on two separate occassions, 4 to 6 weeks apart.
Study NCT02173743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRP
Description: platelet enriched autologous blood plasma
Study NCT02173743 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Regular barbotage/care as usual
Study NCT02882659 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Killer Cell (DKC)
Description: DKC is a hybrid cell type capable of dual functionality, i.e. cytotoxicity and antigen presentation, similar to NK cells and DCs, respectively.
Study NCT00730639 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-936558 (MDX-1106)
Description: Solution, Intravenous, 0.1 mg/kg - 10 mg/kg, Every 2 weeks, 3 years depending on response
Study NCT00730639 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-936558 (MDX-1106)
Description: Solution, Intravenous, 1 - 10 mg/kg, Every 2 weeks, 3 years depending on response
Study NCT00730639 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-936558 (MDX-1106)
Description: Solution, Intravenous, 10 mg/kg, Every 2 weeks, 3 years depending on response
Study NCT02189850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI800 - Dose 1
Description: BLI800 oral solution
Study NCT02189850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI800 - Dose 2
Description: BLI800 oral solution
Study NCT01836783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amnion Allograft
Description: Atraumatic extraction and grafting procedures will be followed by insertion of a dental implant into the grafted area at week-8. The implant will be restored and be monitored for 24 months post-insertion. Two special dental cone-beam CT images (pre-baseline and week-7) and a minimum of 6 intraoral radiographs will be taken during the study
Study NCT01836783 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Allograft
Description: Atraumatic extraction and grafting procedures will be followed by insertion of a dental implant into to the grafted area at week-8. The implant will be restored and be monitored for 24 months post-insertion. Two special dental cone-beam CT images (pre-baseline and week-7) and a minimum of 6 intraoral radiographs will be taken during the study
Study NCT04011280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: The ten 30-minute sessions will target core processes in ACT such as acceptance and being present.
Study NCT04011280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: The ten 30-minute sessions will target core processes in ACT such as acceptance and being present.
Study NCT03183882 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personal Feedback
Description: One-time summary report of their individual history of opioid prescribing over the past 14 months
Study NCT03183882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Normative Comparison Feedback
Description: One-time summary report of their individual history of opioid prescribing over the past 14 months WITH comparisons to (a) other providers at their site and (2) other providers at all 15 ED sites with similar prescribing
Study NCT03270865 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAF (Positioning And Fixation device)
Description: Up to 60 Subjects will be evaluating for positioning accuracy and comfort by comparing different methods utilizing the PAF device. Some methods of positioning will be applied and compare for each usability factor X, Y, Z location, and fixation.~The patient will be evaluated before pupil dilation. VA and ophthalmic diagnoses will be recorded.~Pupil position will be recorded using 3 commercial off the shelf cameras when the subject is performing simple ergonomic tasks while looking at a screen presenting images. Each testing session will be limited 20 min long. Subjects will be able to rest within the testing session if required. Total session time per patient will not exceed 30 minutes.
Study NCT02222259 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GA and Integrated Care Plan
Description: The intervention will consist of a Geriatric Assessment conducted by a multidisciplinary geriatric oncology team followed by an integrated care plan developed and implemented by the team for those issues identified in the assessment. The study intervention includes contact with the intervention team at 4 points in time during the study: at baseline (to conduct the assessment and develop the integrated care plan), 2-3 weeks by telephone after the clinic visit to evaluate if the plan needs adjustments, at 3 and 6 months (to evaluate the outcomes of the integrated care plan; i.e., did the patient follow all recommendations of the integrated care plan and did the plan lead to the desired outcomes for the problems identified?
Study NCT04358835 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: 4:1 ratio enteral ketogenic formula within 48 hours of intubation
Study NCT04358835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard of care
Description: standard of care/supportive therapy
Study NCT01988610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 28 days treatment with Mifepristone.
Study NCT01387243 — intervention group
Intervention type: DRUG
Intervention: Orlistat
Description: 60 mg
Study NCT02567487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: Transversus abdominis plane block with levobupivacaine
Study NCT01107431 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-Arabinose and Chromium
Description: Consumed 70 grams of sucrose simultaneously taking a dietary supplement
Study NCT01107431 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose without dietary Supplement
Description: Repeated measures on subjects taking 70 grams of sucrose along with taking a dietary supplement containing L-Arabinose and Chromium
Study NCT01744600 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: The music therapy intervention will consist of individual active music therapy session each week for a period of 22 weeks. Each session will last 30 minutes.
Study NCT01750112 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macrolane VRF20
Description: Injection treatment with Macrolane VRF20
Study NCT03834415 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM17038
Description: Oil drops of L. reuteri containing 1x10>8 CFU
Study NCT03834415 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Probiotics
Description: Oil drops mimicking in consistency and flavor to experimental product
Study NCT04453982 — intervention group
Intervention type: OTHER
Intervention: Human milk donors
Description: Human milk donors for the Rogers Hixon Ontario Human Milk Bank
Study NCT01250379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 10 mg/ kg iv every 2 weeks or 15 mg/kg iv every 3 weeks
Study NCT01250379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Standard chemotherapy (doublets not allowed)
Study NCT01250379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Standard chemotherapy (doublets not allowed)
Study NCT00631748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine fumarate
Description: At baseline, subjects in the experimental group will initially be administered 50 mg/day of Seroquel XR™ (extended release formulation of quetiapine fumarate), to be titrated up to 400 mg/day of Seroquel XR™ by the end of the second week. By the end of week 2, subjects will be stabilized on a dose of 400 mg/day or alternatively 300, 200, 100, or 50 mg/day of study drug, as tolerated. If a subject is unable to tolerate the 50 mg/day dose, he or she will be discontinued from the drug portion of the study.
Study NCT00631748 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo
Description: Subjects randomized to the placebo comparator group will follow the same titration and dosing procedures as the experimental group, but will receive matched placebo tablets.
Study NCT00631748 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive-behavioral Therapy
Description: During the 12 week treatment phase, all subjects attended weekly group cognitive-behavioral therapy sessions. This therapy platform utilized the cognitive-behavioral therapy manual, Seeking Safety. Seeking Safety has been shown to effectively reduce substance use and to improve psychological functioning in a variety of populations.
Study NCT00631748 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral Therapy
Description: During the 12 week treatment phase, all subjects attended weekly group cognitive-behavioral therapy sessions. This therapy platform utilized the cognitive-behavioral therapy manual, Seeking Safety. Seeking Safety has been shown to effectively reduce substance use and to improve psychological functioning in a variety of populations.
Study NCT02188875 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS Text Messages & Fitbit One
Description: The primary aim was to test text-messaging in its basic form to prompt physical activity. A secondary aim was to examine the effects of the Fitbit One.
Study NCT02188875 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit One Only
Description: Active controls received a Fitbit One to facilitate self-monitoring (and no text messages)
Study NCT01319409 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anatomic Double-Bundle ACL Reconstruction
Description: Surgical reconstruction of the posterolateral (PL) and anteromedial (AM) bundles of the ACL using an autograft quadriceps tendon with a bone block that is split into 2 free arms to recreate the AM and PL bundles. The bone block is placed in a single femoral tunnel located in the center of the femoral ACL insertion site. The free ends of the graft are be placed in 2 separate tunnels located in the centers of the tibial insertions for the PL and AM bundles. The PL bundle is fixed with the knee in full extension and the AM bundle is fixed with the knee at 45 degrees of flexion.
Study NCT01319409 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anatomic Single-Bundle ACL Reconstruction
Description: Surgical reconstruction of the ACL using a single autograft quadriceps tendon with a bone block. The free end of the graft is not split. The bone block is placed in a single femoral tunnel located in the center of the femoral ACL insertion site. The single free end of the graft is placed in a single tibial tunnel located in the center of the tibial ACL insertion site. The graft is fixed with the knee in 10 to 20 degrees of flexion.
Study NCT04418076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group A_No feedback
Description: In the control (Group A), the feedback option will be deactivated on the device on the TowerView Health® smart pill box, effectively serving to only monitor natural pill-taking patterns.
Study NCT04418076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group B_Automated feedback
Description: For participants in Group B (automated feedback), missed dosages will prompt an automated text message to be sent to the participants' smartphone. The TowerView Health® pill box consists of in-built alarm and flashing color lights, and the ability to send text messages to the participants' phone either as reminder in the event of missed dosage or a message of encouragement when all dosages are taken.
Study NCT04418076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group C_Automated feedback + Clinician feedback
Description: For participants in Group C, the survey app responses will be assessed each week by the RA who in turn will communicate the results to a clinical nurse. The clinical nurse will be funded through this study; he/she will be responsible for providing personalized feedback to all Group C participants. The clinic nurse will contact the subject with appropriate feedback about their health behavior and suggestions for sustained adherence.
Study NCT04418076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group D_Automated feedback + Social Network feedback
Description: For participants in Group D, a social network designee will be chosen based on the names provided by the participants during screening. One social network designee will be consented and chosen to send the participant a weekly text reminder the participant to take their medication. The text for the message will be chosen by the social network designee.
Study NCT03225053 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEP® technique
Description: G1 (n = 15), referred to as LMF, will be submitted to the myofascial release technique consisting of: classic massage (superficial sliding, deep sliding, pumping-kneading, pulse and four-finger smear and sliding) Minutes. G2 (n = 15) will be applied to the MEP® technique, in which the needles will be introduced in three occasions during each session, in different points of the musculature of the most painful region, for a total of 3 minutes. The G3 (n = 15) will execute the two techniques above, being applied the first version Myofascial and later to the MEP®. G4 (n = 15) will be the control group, not performing any of the interventions. The reevaluations will occur immediately and after 48 hours of the intervention.
Study NCT00644787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl 1-day transdermal patch (Titration Phase)
Description: Fentanyl 1-day application transdermal patch releasing the drug at the rate of 12.5 mcg/hr applied once daily, and maintained for 2 days. Dose escalation or reduction is done as per Investigator's discretion (maximum applied dose is 100 mcg/hr) up to Day 11 and then dose is fixed up to end of treatment period, that is Day 14.
Study NCT04294810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.
Study NCT04294810 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching Placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
Study NCT00644787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl 1-day transdermal patch (Double Blind Phase)
Description: Fentanyl 1-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
Study NCT00644787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl 3-day transdermal patch (Double Blind Phase)
Description: Fentanyl 3-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
Study NCT00644787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to fentanyl 3-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase for 10 days.
Study NCT00644787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo matching to fentanyl 1-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase for 10 days.
Study NCT00999531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9411
Description: Inhaled GS-9411 dissolved in sterile saline
Study NCT00999531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled Placebo, sterile saline
Study NCT01528514 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Curcuminoids
Description: Curcuminoids in capsule form, 4 capsules four times daily (4 grams/day)
Study NCT01528514 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in capsule form, 4 capsules 4 times/day
Study NCT04901208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine pod
Description: Nicotine pods administered to individuals who use Juul
Study NCT04901208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo pod
Description: Nicotine-free pods administered to individuals who use Juul
Study NCT03216473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neuronox
Description: Clostridium Botulinum Toxin A 100 U
Study NCT03216473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox
Description: Clostridium Botulinum Toxin A 100 U
Study NCT01984268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTHAR
Study NCT02549209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg will be administered every 3 weeks for all subjects
Study NCT02549209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: For subjects with no prior therapy, paclitaxel will be dosed at 175mg/m2 and be administered as a 3-hour continuous IV infusion.~Subjects with prior XRT/platinum-based chemotherapy must initiate paclitaxel at 135mg/m2 and be administered as a 3-hour continuous IV infusion.
Study NCT02549209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: For subjects with no prior therapy, carboplatin will be dosed at an AUC of 6 and given as an IV infusion in 250ml of D5W over 30 minutes.~Subjects with prior XRT/platinum-based chemotherapy must initiate carboplatin at an AUC of 5 given as an IV infusion in 250ml of D5W over 30 minutes.
Study NCT01452152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: clopidogrel 75 mg/day plus aspirin 81-162 mg/day for one year
Study NCT01452152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prasugrel
Description: Prasugrel 5-10 mg/day plus aspirin 81-162 mg/day for one year
Study NCT04069065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conversion to Once-daily Tacrolimus
Description: * Orally, once-daily in the morning~* The first dose is converted to approximately 100% of the existing daily dose, taking into account the subject's blood concentration, after which the investigator check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3\~10ng/ml.
Study NCT03713164 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pomegranate Juice
Description: Volunteers will consume either one dose of pomegranate juice or pure ellagic acid, an ellagitannin naturally present in pomegranates.
Study NCT03713164 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ellagic Acid
Description: Volunteers will consume either one dose of pomegranate juice or pure ellagic acid, an ellagitannin naturally present in pomegranates.
Study NCT01234272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine
Description: ITM-IVPCA: intrathecal administration of 0.3 mg morphine before induction of general anesthesia and application of IVPCA (basal infusion: fentanyl 0.4mcg/kg/hr, bolus: 0.16mcg/kg of fentanyl with a lock out time of 15 min)